Botfet / Company detail

XENE

rejected

Xenon Pharmaceuticals Inc.

biotech

Moat scoreNot available: not scored quality failout of 100
Rejectionquality_fail

The numbers

Financial metrics

Quality gate and thesis context
Roic-39.6%
Gross Margin66.1%
Revenue Cagr-36.2%
Fcf Conversion80.9%
Fcf Yield-8.1%
Interest Coverage0.0x
Market Cap B$3.4B
PeNot available: not applicable loss making
Quality PassFail
Founder LedNo
Thesis AlignedYes
Moat QuantNot available: not scored quality fail

Why it may endure

Moat breakdown

Quant: Not available: not scored quality fail · Curator: Not available: not scored quality fail
Market Share StabilityNot available: not scored quality fail
Network EffectsNot available: not scored quality fail
Pricing PowerNot available: not scored quality fail
Regulatory MoatNot available: not scored quality fail
Switching CostsNot available: not scored quality fail
ConvictionNot available: not scored quality fail
LeadershipNot available: not scored quality fail
VisionNot available: not scored quality fail
← Back to the full screener